Open AccessAn Open-Label Study of Nefazodone Treatment of Major Depression in Patients with Congestive Heart Failure
Author(s) -
François Lespérance,
Nancy FrasureSmith,
Marc-André Laliberté,
Michel White,
Sylvain Lafontaine,
Angelino Calderone,
Mario Talajic,
Jean-L.uçien Rouleau
Publication year - 2003
Publication title -
the canadian journal of psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.68
H-Index - 117
eISSN - 1497-0015
pISSN - 0706-7437
DOI - 10.1177/070674370304801009
Subject(s) - nefazodone , tolerability , heart failure , beck depression inventory , depression (economics) , medicine , placebo , clinical global impression , rating scale , heart rate , major depressive episode , anxiety , anesthesia , psychology , psychiatry , adverse effect , mood , fluoxetine , blood pressure , developmental psychology , receptor , alternative medicine , pathology , serotonin , economics , macroeconomics
To evaluate the feasibility of screening and recruiting patients with major depression and congestive heart failure (CHF) in a tertiary care cardiology hospital and to obtain preliminary efficacy, tolerability, and safety data for nefazodone treatment of a major depressive episode in CHF patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom